Skip to content

Netherlands Society of Gene and Cell Therapy

  • About
    • History
    • Mission
    • Board Members
    • Committees
    • Honorary Members
  • Education
    • Gene Therapy Basics
    • Cell Therapy Basics
    • Antisense Oligonucleotide Therapy Basics
    • Approved Therapies
  • Research
    • Gene and Cell Therapy in the Netherlands
      • Academic research groups
      • National initiatives
    • Greiner Award
    • NVGCT Outstanding Achievement Award
      • 2023 NVGCT Outstanding Achievement Award
      • 2022 NVGCT Outstanding Achievement Award
      • 2021 NVGCT Outstanding Achievement Award
      • 2020 NVGCT Outstanding Achievement Award
      • 2019 NVGCT Outstanding Achievement Award
    • Research News
    • Human Gene Therapy
    • Other Journals
    • Useful Links
    • Research Image Gallery
    • Research vacancies
  • Events
    • Webinars
    • Calendar
    • Annual Symposium
      • Annual Symposium 2025
    • Past events
      • Annual Symposium 2024
      • Annual Symposium 2023
      • Annual Symposium 2022
      • Annual Symposium 2020-2021
      • Spring Symposium 2019
      • Spring Symposium 2018
      • Patiënteninformatiedag Gentherapie
  • Get Involved
    • Become a Member
    • Become a sponsor
    • Contact
  • Patient Info (NL)
    • Dossier Gentherapie Stichting BWM
    • Patiënteninformatiedag Gentherapie
    • Veelgestelde vragen
  • Sign in

News

Posted on 28/06/202128/06/2021

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

Posted on 18/05/202108/07/2024

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

Posted on 11/05/202108/07/2024

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Posted on 29/04/202108/07/2024

Adverum Biotechnologies announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema

Posted on 29/03/202108/07/2024

Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of HCC in HOPE-B pivotal trial

Posts navigation

Previous page Page 1 … Page 4 Page 5 Page 6 … Page 17 Next page

Upcoming events

Jun
10
Tue
09:00 NVGCT Annual Symposium 2025 @ De Werelt
NVGCT Annual Symposium 2025 @ De Werelt
Jun 10 @ 09:00 – Jun 11 @ 17:00
NVGCT Annual Symposium 2025 @ De Werelt | Lunteren | Gelderland | Netherlands
Oct
29
Wed
all-day RNA Horizons 2025 Therapeutic Sy... @ NH Hotel Palermo
RNA Horizons 2025 Therapeutic Sy... @ NH Hotel Palermo
Oct 29 – Oct 31 all-day
RNA Horizons 2025 Therapeutic Symposium @ NH Hotel Palermo | Palermo | Sicilia | Italy
View Calendar
Add
  • Add to Timely Calendar
  • Add to Google
  • Add to Outlook
  • Add to Apple Calendar
  • Add to other calendar
  • Export to XML
  • LinkedIn
  • X
Privacy Statement Proudly powered by WordPress